At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity

European Journal of Immunology

Volumn 43, Issue 5, 2013, Pages 1383-1388

  Danielou Lazareth, Anne ^a   Henry, Guylaine ^a   Geromin, Daniela ^a   Khaznadar, Zena ^b,c   Briere, Josette ^a,b,c   Tamouza, Ryad ^a,b   Cayuela, Jean Michel ^a   Thieblemont, Catherine ^a,b,c   Toubert, Antoine ^a,b,c   Dulphy, Nicolas ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

CD137; CD16; Diffuse large B cell lymphoma; Innate immunity; NK cell

Indexed keywords

CD137 ANTIGEN; CD16 ANTIGEN; INTERLEUKIN 2; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SAMPLING; BURKITT LYMPHOMA; CELL FUNCTION; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CELL DEGRANULATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; RECEPTORS, IGG;

EID: 84876822432     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242733     Document Type: Article

References (29)

1. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P. et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002. 346: 235-242.
2. Weiner, G. J., Rituximab: mechanism of action. Semin. Hematol. 2010. 47: 115-123.
3. Kuriyama, Y., Nakano, M., Kawanishi, Y., Iwase, O., Aizawa, S. and Toyama, K., Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas. Leukemia 1995. 9: 2123-2126.
4. Palmer, S., Hanson, C. A., Zent, C. S., Porrata, L. F., Laplant, B., Geyer, S. M., Markovic, S. N. et al., Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br. J. Haematol. 2008. 141: 607-614.
5. Tursz, T., Dokhelar, M. C., Lipinski, M. and Amiel, J. L., Low natural killer cell activity in patients with malignant lymphoma. Cancer 1982. 50: 2333-2335.
6. Burger, J. A., Ghia, P., Rosenwald, A. and Caligaris-Cappio, F., The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009. 114: 3367-3375.
7. Glas, A. M., Knoops, L., Delahaye, L., Kersten, M. J., Kibbelaar, R. E., Wessels, L. A., van Laar, R. et al., Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J. Clin. Oncol. 2007. 25: 390-398.
8. Taskinen, M., Karjalainen-Lindsberg, M. L., Nyman, H., Eerola, L. M. and Leppa, S., A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 2007. 13: 5784-5789.
9. Plonquet, A., Haioun, C., Jais, J. P., Debard, A. L., Salles, G., Bene, M. C., Feugier, P. et al., Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann. Oncol. 2007. 18: 1209-1215.
10. Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J. et al., Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 2004. 10: 2253-2264.
11. Lanier, L. L., Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 2008. 9: 495-502.
12. El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D., Mackie, S. L., Morgan, A. W., Cook, G. et al., The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007. 67: 8444-8449.
13. Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M. et al., NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 2009. 119: 1251-1263.
14. Vinay, D. S. and Kwon, B. S., 4-1BB signaling beyond T cells. Cell Mol. Immunol. 2011. 8: 281-284.
15. Cooper, M. A., Fehniger, T. A. and Caligiuri, M. A., The biology of human natural killer-cell subsets. Trends Immunol. 2001. 22: 633-640.
16. Koene, H. R., Kleijer, M., Algra, J., Roos, D., von dem Borne, A. E. and de Haas, M., Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997. 90: 1109-1114.
17. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754-758.
18. Veeramani, S., Wang, S. Y., Dahle, C., Blackwell, S., Jacobus, L., Knutson, T., Button, A. et al., Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011. 118: 3347-3349.
19. Bryceson, Y. T., March, M. E., Barber, D. F., Ljunggren, H. G. and Long, E. O., Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 2005. 202: 1001-1012.
20. Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Muller, A. et al., CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011. 117: 2423-2432.
21. Houot, R., Kohrt, H. E., Marabelle, A. and Levy, R., Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol. 2011. 32: 510-516.
22. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R. et al., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010. 115: 4393-4402.
23. Sehn, L. H., Assouline, S. E., Stewart, D. A., Mangel, J., Gascoyne, R. D., Fine, G., Frances-Lasserre, S. et al., A phase I study of obinutuzumab induction followed by two years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012. 119: 5118-5125.
24. Salles, G., Morschhauser, F., Lamy, T., Milpied, N. J., Thieblemont, C., Tilly, H., Bieska, G. et al., Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012. 119: 5126-5132.
25. Sehn, L. H., Goy, A., Offner, F. C., Martinelli, G., Friedberg, J., Lasserre, S. F., Fine, G. et al., Randomized phase II trial comparing GA101 (Obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. ASH Annual Meeting Abstracts 2011. 118: (Abstract 269).
26. dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011. 25: 101-109.
27. Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D. et al., Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 2012. 122: 1066-1075.
28. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N. Engl. J. Med. 1993. 329: 987-994.
29. low NK cell subset dominates the early post-transplant period following HLA-matched hematopoietic stem cell transplantation. J. Immunol. 2008. 181: 2227-2237.